Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a gentle brain zap restore sensation after chemotherapy?

NCT ID NCT07673614

Symptom relief Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jul 17, 2026 · Updated 4 times

Summary

This trial tests whether a non-invasive brain stimulation technique called transcranial direct current stimulation (tDCS) can help cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN). CIPN causes numbness, tingling, pain, and movement problems. The study compares active tDCS to a sham (fake) procedure in 50 cancer survivors who are no longer on active treatment. Researchers measure changes in vibration and cold detection, balance, and walking ability right after stimulation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS)
What this could lead to
If effective, tDCS could offer a non-drug way to ease nerve pain and improve movement in cancer survivors with lasting chemotherapy side effects.
What could go wrong
This is a small, early-stage trial with 50 people. The effects are temporary, and it may not work for everyone or lead to a lasting treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 to 85 years of age * Diagnosis of cancer, stages I-IV * Cancer survivor (not currently receiving chemotherapy, radiation, or immunotherapy) * Presence of CIPN defined as new, length-dependent numbness, tingling, and/or pain that developed with neurotoxic chemotherapy * CIPN20 score ≥ 20 * Able to walk unassisted * Proficient in English Exclusion Criteria: * Known brain metastases * Known neurological conditions aside from chemotherapy-induced peripheral neuropathy (CIPN) * History of brain or spinal surgery * Neuropathy other than CIPN * Significant hearing or vision deficits * Vestibulopathy * Currently receiving chemotherapy, radiation therapy, or immunotherapy * Contraindications to transcranial direct current stimulation (tDCS), including recent seizures * Presence of metallic objects in the head * Presence of specific implanted medical devices (e.g., deep brain stimulator, cochlear implant, vagus nerve stimulator, spinal cord stimulator, pacemakers, and intracardiac devices) * Active scalp dermatological conditions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy-induced peripheral neuropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer chemotherapy-induced neuropathy hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy-induced peripheral neuropathy Hematopoietic and lymphatic system neoplasm Malignant solid neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.